STOCK MARKET BSE NSE

COVID-19: Remdesivir to take at least two weeks to hit the market

After the CDSCO permit, it will take at least a couple of days for state government-level clearances to start manufacturing, pushing its market entry to July first or second week.

Published: 20th June 2020 12:48 AM  |   Last Updated: 20th June 2020 10:54 AM   |  A+A-

A vial of the investigational drug remdesivir is visually inspected at a Gilead Sciences manufacturing site in US

A vial of the investigational drug remdesivir is visually inspected at a Gilead Sciences manufacturing site in US. (File photo| AP)

Express News Service

HYDERABAD: Repurposed anti-viral drug remdesivir, which promises to help reduce hospital time of COVID-19 patients, might take at least two more weeks to hit the Indian market.

A few Indian pharma companies, including two in Hyderabad, have license from the US-based Gilead Life Sciences to manufacture remdesivir, which has been allowed by Indian Council of Medical Research (ICMR) for emergency use for COVID-19 treatment.

While senior officials of Hetero Drugs and Dr Reddy’s Laboratories did not comment on details on their production capacity, they expect approval by Central Drugs Standard Control Organisation (CDSCO) by June-end for its manufacture.

After the CDSCO permit, it will take at least a couple of days for state government-level clearances to start manufacturing, pushing its market entry to July first or second week. In its updated Clinical Management Protocol for COVID-19, ICMR included remdesivir as an investigational therapy. In TS, remdesivir is being tested at Gandhi Hospital.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp